Merck is entering a new era, with โปรโมชั่น slotxo sweeping changes across its executive suite and the spinoff off its women's health and other businesses, a bid to enable both resulting companies to grow faster.

The massive management makeover, mostly triggered by longtime Chief Executive Ken Frazier's upcoming retirement, occurs as the drugmaker says hits to sales of many of its medicines amid lockdowns and other impacts from the coronavirus pandemic will lessen and sales will rise over the rest of the year.

Frazier, who has run Merck & Co since January 2011, oversaw a quadrupling of revenue and Merck's emergence as a powerhouse in cancer drugs over the decade.

Now 66 and the only Black CEO of a major drugmaker, Frazier will retire on June 30, causing a domino effect of job changes. He'll be succeeded by Chief Financial Officer Rob Davis, who will be replaced by company treasurer Caroline Litchfield. Her replacement hasn’t been named yet.

Michael Nally, head of marketing for Merck’s huge prescription drug business and a candidate to replace Frazier, departed last month. The chief commercial officer for that business, Frank Clyburn, will become its president and lead both commercial strategy and marketing.

And in January, Dr Dean Li became head of Merck’s highly regarded research labs, taking over for now-retired Roger Perlmutter.

On Thursday, Merck reported its first-quarter profit dipped 1 per cent as people continued to put off doctor and hospital visits early this year due to the COVID-19 pandemic, and it spent more on research and production.

While it fell short of Wall Street profit expectations, Merck maintained its profit forecast for the year.